16 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27816515	143	Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors.	Merck
26762835	342	Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).	Icahn School Of Medicine At Mount Sinai
23570561	80	Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.	The Scripps Research Institute
23416002	126	Amino acid derived quinazolines as Rock/PKA inhibitors.	Translational Research Institute
18183025	12060	A quantitative analysis of kinase inhibitor selectivity.	Ambit Biosciences
17935989	146	Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics.	Abbott Laboratories
22037378	31824	Comprehensive analysis of kinase inhibitor selectivity.	Ambit Biosciences
20860370	83	Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.	Dana-Farber Cancer Institute
19654408	2521	AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).	Ambit Biosciences
20684608	73	Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors.	The Scripps Research Institute
20346655	117	Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases.	Abbott Laboratories
19837589	52	Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors.	Translational Research Institute And Department Of Molecular Therapeutics
18990570	72	Chroman-3-amides as potent Rho kinase inhibitors.	The Scripps Research Institute
1968985	56	Characteristics of 125I-iodocyanopindolol binding to beta-adrenergic and serotonin-1B receptors of rat brain: selectivity of beta-adrenergic agents.	Niigata College Of Pharmacy